Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
News, developments and strategies related to eClinical, data management, data collection, ePRO, and more information technology used in the drug development chain. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
The Emergence of Business Insights
Enrollment Performance Assessment
Whenever implementing data analysis, it is important to first define research objectives; establishing clearly defined research objectives not only save study teams time, but they also allow study teams to implement meaningful business and clinical trial performance strategies. The objectives of this performance assessment were to (a) identify underperforming sites and (b) uncover strategies that outperforming sites were implementing to maximize the success of enrollment activities across all sites.
The first step was to perform a regression analysis on two factors involving enrollment performance, which included subjects screened VS randomized. In other words, we wanted to identify whether screening subjects had any statistical effect on randomizing subjects. Table 1 demonstrates the results of the regression analysis.
With a T-Stat figure of 33.224 and a T-Critical figure of 1.969, we can determine that T-Stat > T-Critical and we can reject the null hypothesis (H0). This means that there is a statistically significant relationship between screening and randomizing subjects; each subject screened is equivalent to a 0.463 subject randomization rate. In other words, a site will need to screen approximately 2 subjects in order to randomize 1 subject, and since this figure is statistically significant, this rate applies towards all sites in a normally distributed scenario with 95% confidence.
Figure 1 demonstrates the concentration of subjects screened VS randomized by study site in the form of a plot. Darker/bolder circles represent higher site concentrations, whereas fainter circles represent lower concentrations. For example, the first vertical line of circles on the bottom left hand side of the graph suggests that many sites (especially on the bottom) screened less than 10 subjects and did not randomize any subjects.
Turning Underperformance Identification into Effective Business Solutions
An effective method involves in-depth focus group and individual interview research with study sites & CRAs, and correspondingly, surveying study sites in order to quantify and verify factors affecting outperformance/underperformance. Subsequently, the study team could leverage research findings in order to influence underperforming sites to perform more optimally, and average sites to outperform (ultimately try to push the slope of the orange line downwards, and the screened/randomization ratio higher).
Expert site communication services and continual analytical performance assessments are essential operational activities in order to determine the effectiveness of the initiatives. This customized assessment and interpretation analysis is merely one of many that could be conducted in order to identify study site trial activity and enrollment underperformance.